- Home
- JFU vs BRTX Comparison
JFU vs BRTX Comparison
Compare JFU & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- BRTX
- Stock Information
- Founded
- JFU 2006
- BRTX 1997
- Country
- JFU China
- BRTX United States
- Employees
- JFU N/A
- BRTX N/A
- Industry
- JFU Finance: Consumer Services
- BRTX Managed Health Care
- Sector
- JFU Finance
- BRTX Health Care
- Exchange
- JFU Nasdaq
- BRTX Nasdaq
- Market Cap
- JFU N/A
- BRTX 12.2M
- IPO Year
- JFU 2019
- BRTX N/A
- Fundamental
- Price
- JFU $1.58
- BRTX $1.82
- Analyst Decision
- JFU
- BRTX Strong Buy
- Analyst Count
- JFU 0
- BRTX 1
- Target Price
- JFU N/A
- BRTX $18.00
- AVG Volume (30 Days)
- JFU 20.6K
- BRTX 23.7K
- Earning Date
- JFU 01-01-0001
- BRTX 05-13-2025
- Dividend Yield
- JFU N/A
- BRTX N/A
- EPS Growth
- JFU N/A
- BRTX N/A
- EPS
- JFU 0.09
- BRTX N/A
- Revenue
- JFU $40,614,155.00
- BRTX $401,000.00
- Revenue This Year
- JFU N/A
- BRTX $446.88
- Revenue Next Year
- JFU N/A
- BRTX $39.53
- P/E Ratio
- JFU $15.88
- BRTX N/A
- Revenue Growth
- JFU N/A
- BRTX 175.03
- 52 Week Low
- JFU $1.01
- BRTX $1.03
- 52 Week High
- JFU $3.60
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- JFU 65.75
- BRTX 54.29
- Support Level
- JFU $1.33
- BRTX $1.76
- Resistance Level
- JFU $1.75
- BRTX $1.78
- Average True Range (ATR)
- JFU 0.19
- BRTX 0.07
- MACD
- JFU 0.05
- BRTX 0.01
- Stochastic Oscillator
- JFU 77.03
- BRTX 72.24
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.